← Archive

Built on Borrowed Time: Maternal Health Telehealth Runs Through 2027. The TMaH Payoff Arrives in 2028.

The Telehealth Cliff for Maternal Health — companies that used the TMaH infrastructure phase to build distribution via home telehealth channels may enter the value-based performance phase without the billing infrastructure they used to build it.

Pediatric Health Dispatch | Deep Dispatch | June 19, 2026

The Fourth Extension Is Not the Same as Permanence

The Consolidated Appropriations Act, 2026, signed in March, extended a set of Medicare and Medicaid telehealth provisions that have been subject to emergency authorization since 2020. The provisions most material to maternal-pediatric health tech include three distinct flexibilities, each worth understanding separately rather than as a single undifferentiated "telehealth extension."

The first is originating site flexibility. Before the COVID public health emergency, Medicare and Medicaid typically required patients to receive telehealth from an approved medical facility rather than from home. The waiver allows home-based telehealth visits, which is structurally fundamental to every maternal health platform that conducts remote prenatal check-ins, postpartum mental health sessions, or blood pressure monitoring with a pregnant patient at home. Babyscripts, Pomelo Care, and the obstetric-practice management tools built on Medicaid managed care contracts were all designed around the assumption that home is a valid originating site.

The second provision is FQHC distant-site authorization. Federally Qualified Health Centers serve as both clinical sites and billing entities for a significant share of Medicaid maternal health encounters. The CAA 2026 extended FQHCs' authority to serve as distant sites in telehealth arrangements, which is the provision that makes FQHC-partnered platforms like Nest Health and Nadia Care financially viable. An FQHC partnership without distant-site telehealth billing authority is a referral relationship, not a reimbursable care-delivery model.

The third is the mental health in-person visit modification. Prior telehealth policy required an in-person visit before initiating telehealth-based mental health treatment, a requirement that created documented attrition in pediatric behavioral health specifically, where scheduling delays add weeks of caregiver burden. The CAA 2026 reduced the frequency of required in-person visits without eliminating the requirement entirely, which lowered the activation threshold for Cartwheel Care and Hazel Health while preserving some friction for pure virtual-only mental health initiation.

All three of these provisions are currently authorized through the end of 2027. The qualifier is doing a lot of work in that sentence. Congress has renewed some version of these provisions four consecutive times since the COVID public health emergency ended. Each renewal was framed as temporary. None was converted to permanent law. The telehealth industry has lobbied for permanence since 2021, and the argument gets made with increasing force and increasing data each cycle. It has not succeeded.

The practical consequence of recurring renewal is that companies building multi-year operating plans with Medicaid telehealth revenue have had to make an implicit assumption: that another extension will come. In four cycles, that assumption has proved correct. It is not a guarantee. It is a pattern that happens to have held, and treating a pattern as a guarantee is a specific type of risk that shows up in business models before it shows up in investor memos.

The TMaH Timing Problem

The telehealth expiration problem would be merely inconvenient if the business models depending on it were generating revenue now. The deeper issue is that several maternal health platforms are using the telehealth window to accumulate distribution and outcomes data, with the payoff expected in a performance-incentive phase that does not begin until 2028.

The Transforming Maternal Health model is the specific collision point. Four states (California, Minnesota, New York, and Arkansas) are now active TMaH participants, with CMS providing each up to $17 million in cooperative agreement funding to build data infrastructure, expand care teams, and prepare for value-based performance measurement. The model is explicitly sequenced: infrastructure investment in years one through three, provider infrastructure payments beginning by 2027, and quality and performance incentive payments starting in year four.

New York's TMaH focus is specifically on remote patient monitoring for hypertension and depression screening. Minnesota's includes home monitoring as a core component. Both are exactly the capabilities that RPM-dependent maternal health companies deliver. A company like Babyscripts, which built its platform specifically for obstetric RPM and operates with more than 70% Medicaid users, is structurally aligned with what TMaH states are trying to build. The TMaH infrastructure phase is the window for companies like Babyscripts to establish themselves inside state Medicaid programs as documented providers with measurable outcomes before the performance-incentive phase begins.

The timing problem is this: the infrastructure and data-accumulation phase runs roughly 2025 through 2027. The performance-incentive phase begins in 2028. The telehealth extensions that make Medicaid-based RPM economically viable for home-based maternal patients run through the end of 2027. If Congress does not extend those provisions, the companies that used years one through three to build TMaH distribution via home telehealth channels will enter the VBP performance phase without the billing infrastructure they used to build it.

This is not a speculative scenario. It is the literal timeline intersection between two policies that were written by different offices without coordination. The CAA 2026 telehealth extension and the TMaH cooperative agreement structure were not designed together. Their collision in 2027 is an artifact of independent legislative calendars, not a policy choice anyone made.

There is a compounding dynamic worth naming. PHD analyzed two weeks ago how the CMS directed-payments cap and the proposed elimination of Title X and Healthy Start create simultaneous pressure on Medicaid maternal health business models. The telehealth timeline adds a third pressure point with a specific date attached. A Medicaid-first maternal health operator is currently managing three converging risks: a proposed cap on directed-payment financing mechanisms flowing through managed care contracts, proposed cuts to the public-health infrastructure that functions as a patient acquisition channel, and a telehealth expiration that would change the clinical delivery mechanism in 2027. The companies that survive this are those that designed for each risk independently. The ones that fail will be those that treated any one of the three as a baseline assumption rather than a variable.

Segmenting Exposure

Not every maternal-pediatric health tech company is equally exposed to a 2027 telehealth expiration. The exposure gradient runs cleanly along the axis of Medicaid telehealth dependence versus commercial contract stability.

Maven Clinic operates at the insulated end. Its 2,300-plus enterprise clients are primarily self-insured employers and commercial health plans whose contracts with Maven are structured around benefits administration, not federal telehealth billing codes. A 2027 expiration would create friction in any Medicaid-facing programs Maven operates, but the core commercial model (the one that generated the outcomes metrics anchoring its $1.7 billion valuation) runs on employer-benefit contract terms that do not depend on Medicaid originating-site flexibility. Maven also used its March 2026 direct-to-consumer launch to open a direct-pay channel, adding a third commercial insulation layer on top of employer and health-plan contracts.

Pomelo Care sits in the partially exposed middle. Its $92 million Series C reflects a business model spanning both commercial and Medicaid populations, with payer contracts as the growth engine. Pomelo's 25-million-covered-lives figure includes Medicaid lives served through payer partnerships, and the company has moved explicitly toward payer-aligned value-based contracting rather than pure fee-for-service billing. Whether Pomelo's payer contracts are structured around state-plan covered services (which can be maintained without federal waivers) or around federally extended flexibilities depends on contract-level details that are not publicly disclosed. That is precisely the question investors should be asking, and the absence of a public answer is itself a signal about where the exposure sits.

Babyscripts is most directly in the exposure zone. More than 70% of its users are Medicaid beneficiaries. Its clinical model centers on connected devices and RPM codes for obstetric monitoring, delivered to patients at home. That is the precise configuration that originating-site flexibility was designed to enable. A 2027 expiration without another renewal would require Babyscripts to renegotiate its clinical delivery model with every Medicaid managed care partner relying on home-based RPM as a covered service. The renegotiation is possible. It is not fast, and it is not free. And it would happen at the same moment Babyscripts should be transitioning from infrastructure investment to performance-incentive capture in TMaH states.

The FQHC-partnered platforms carry a specific risk that receives less attention than the originating-site question. Their business model depends on FQHCs maintaining distant-site billing authority. Removing that authority would not just affect the platforms directly. It would change the financial model of the FQHC itself, which then changes the economics of the partnership. In a constrained FQHC environment, the telehealth service line that looks optional from a billing standpoint gets cut first.

For Cartwheel Care and Hazel Health, the school-district distribution channel provides partial insulation. District contracts fund access without making schools the clinical operator, and reimbursement runs through insurance rather than federal telehealth waivers directly. The mental health in-person visit modification matters specifically for initiating new care relationships, and rolling it back would reintroduce attrition at exactly the moment those companies are trying to scale district enrollment. It is an operational problem, not an existential one, provided the commercial and Medicaid insurance channels themselves remain intact.

The strategic read is not complicated, though it is inconvenient. Companies with diversified payer channels, direct payer contracts at state-plan rates, and commercial anchors should model a 2027 expiration as a manageable operational challenge. Companies with Medicaid-first models built around federal telehealth billing codes should treat permanence of those codes as a risk to be engineered around, not a political outcome to be assumed.

Congress's track record on telehealth permanence is four renewals without commitment. The fifth may arrive before December 2027. The companies positioned to survive either outcome are not the ones lobbying hardest for permanence. They are the ones building contracts that do not require it.

---

What we're watching

• Whether Congress includes a permanent or multi-year telehealth extension in a year-end 2026 spending package, which would be the next realistic legislative vehicle and would remove the 2027 cliff for companies in the middle of TMaH infrastructure buildout. A multi-year extension buys time; only a permanent extension resolves the structural risk.
• Whether CMS provides explicit guidance on how TMaH participating states should structure RPM reimbursement in a scenario where federal telehealth billing flexibilities lapse. The TMaH cooperative agreement does not appear to address the federal-extension dependency directly, and that silence is a gap CMS should fill before 2027 puts the question to states under pressure.
• Whether any Medicaid-facing maternal health platform publicly discloses payer-contract structures designed to maintain RPM reimbursement independent of federal originating-site waivers. A company that can point to state-plan covered services as its billing foundation, rather than federally extended flexibilities, has engineered around the risk in a way that is verifiable. One that cannot is carrying an undisclosed dependency.

---